Lansing Management LP Reduces Holdings in Zoetis Inc. (NYSE:ZTS)

Lansing Management LP trimmed its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 73.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,131 shares of the company's stock after selling 55,777 shares during the quarter. Zoetis accounts for approximately 2.9% of Lansing Management LP's holdings, making the stock its 7th largest position. Lansing Management LP's holdings in Zoetis were worth $3,280,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ZTS. Mission Wealth Management LP lifted its position in shares of Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after buying an additional 59 shares in the last quarter. VeraBank N.A. raised its position in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after purchasing an additional 62 shares during the period. HUB Investment Partners LLC lifted its stake in shares of Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after buying an additional 62 shares in the last quarter. Procyon Advisors LLC boosted its holdings in Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after buying an additional 63 shares during the period. Finally, Coppell Advisory Solutions LLC increased its stake in Zoetis by 18.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after buying an additional 64 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. Company insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ZTS shares. Piper Sandler upped their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Stifel Nicolaus decreased their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Finally, Barclays boosted their target price on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $214.40.

Zoetis Trading Up 0.9 %

ZTS stock traded up $1.47 during midday trading on Friday, reaching $157.12. 1,440,311 shares of the company traded hands, compared to its average volume of 2,473,519. The firm has a market capitalization of $70.10 billion, a price-to-earnings ratio of 28.72, a P/E/G ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The business has a 50 day moving average of $158.54 and a 200-day moving average of $167.65. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.